This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
Context. “Compound 23” (LEO Pharma) is an oral IL-17A protein−protein interaction modulator being developed for psoriasis and other inflammatory diseases.…
molecule
1 year ago ●
5 mins read
Context. BMS-986120 is an oral protease-activated receptor 4 (PAR4) inhibitor that was being developed for arterial thrombosis. PAR4 was long…
molecule
1 year ago ●
5 mins read
Context. EZM0414 (Epizyme, Inc.) is an oral SETD2 inhibitor being developed for hematological malignancies. Although several genetic studies have proposed…
molecule
1 year ago ●
5 mins read
Context. DNL201 (Denali Therapeutics) is an oral, CNS-penetrating, ATP-competitive leucine-rich repeat kinase 2 (LRRK2) inhibitor being developed for Parkinson’s disease…
molecule
1 year ago ●
6 mins read
Context. Iclepertin (BI 425809; Boehringer Ingelheim) is an oral glycine transporter-1 (GlyT1) inhibitor being developed for cognitive impairment associated with…
molecule
1 year ago ●
4 mins read
Context. BMS-986339 (BMS) is an oral farnesoid X receptor (FXR) agonist being developed for nonalcoholic steatohepatitis (NASH). Considered the master…
molecule
1 year ago ●
4 mins read
Load More
